Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | SSTR5 | P35346 | 8/20 | 0.87 |
| ▸ | EED | O75530 | 2/20 | 0.79 |
| ▸ | HRH1 | P35367 | 2/20 | 0.79 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | HLA-A | P04439 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | FYN | P06241 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmetheylastemizole SCHEMBL29601510 | 1.00 | KCNH2 (1.00) | KCNH2NR4A2SSTR5EEDHRH1 | |
| Desmetheylastemizole SCHEMBL11473379 | 0.99 | KCNH2 (0.98) | KCNH2NR4A2SSTR5EEDHRH1 | |
| Desmetheylastemizole SCHEMBL11473376 | 0.99 | KCNH2 (0.98) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL10428997 | 0.91 | SSTR5 (0.89) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL1100151 | 0.91 | KCNH2 (0.83) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL11487359 | 0.91 | SSTR5 (0.87) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL11571595 | 0.91 | SSTR5 (0.87) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL20128541 | 0.91 | KCNH2 (0.83) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL9580736 | 0.91 | SSTR5 (0.87) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL1100874 | 0.91 | KCNH2 (0.83) | KCNH2NR4A2SSTR5EEDHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4219559-A | N-Heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-26 | — | — | US | claimed |
| EP-0005318-A1 | N-Heterocyclyl-4-piperidinamines, methods for their preparation, pharmaceutical compositions comprising them, intermediates therefor, and method for the preparation of the intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-14 | — | — | EP | claimed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-7541476-B2 | Radiolabeled astemizole and method of making | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7541476-B2 | Radiolabeled astemizole and method of making | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20080193924-A1 | Cardiovascular safety assay | HEYLEN GODELIEVE IRMA CHRISTIN | 2008-08-14 | — | — | US | disclosed |
| US-20080193924-A1 | Cardiovascular safety assay | HEYLEN GODELIEVE IRMA CHRISTIN | 2008-08-14 | — | — | US | disclosed |
| US-20070166229-A1 | Cardiovascular safety assay | HEYLEN GODELIEVE IRMA C M | 2007-07-19 | — | — | US | disclosed |
| US-20070166229-A1 | Cardiovascular safety assay | HEYLEN GODELIEVE IRMA C M | 2007-07-19 | — | — | US | disclosed |
| EP-0005318-B1 | N-HETEROCYCLYL-4-PIPERIDINAMINES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, INTERMEDIATES THEREFOR, AND METHOD FOR THE PREPARATION OF THE INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-01-06 | — | — | EP | disclosed |
| US-4219559-A | N-Heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-26 | — | — | US | disclosed |
| EP-0005318-A1 | N-Heterocyclyl-4-piperidinamines, methods for their preparation, pharmaceutical compositions comprising them, intermediates therefor, and method for the preparation of the intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885NR4A2 1906/4885SSTR5 4672/4885 |
| US-20070166229-A1 | Cardiovascular safety assay | KCNJ2, TNNT2, KCNJ4 | KCNH2 12/4885NR4A2 2147/4885SSTR5 3846/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | KCNH2 4870/4885NR4A2 2712/4885SSTR5 4627/4885 |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885NR4A2 1906/4885SSTR5 4672/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | KCNH2 3957/4885NR4A2 2534/4885SSTR5 4592/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885NR4A2 1906/4885SSTR5 4672/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885NR4A2 1906/4885SSTR5 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.